Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Zarkin GA, Cowell AJ, Hicks KA, Mills MJ, Belenko S, Dunlap LJ, Keyes V. Lifetime benefits and costs of diverting substance-abusing offenders from state prison. Crime Delinq. 2015 Aug;61(6):829-50. doi: 10.1177/0011128712461904
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Novick D, Montgomery W, Brnabic A, Aguado J, Kadziola Z, Peng X, Brugnoli R, Haro JM. Prognostic implications of somatic symptoms in patients with depression. Results from a three-month, prospective, observational study from Asia. Poster presented at the 28th CINP World Congress of Neuropsychopharmacology; June 3, 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun; 15(1):191. doi: 10.1017/S1461145712000508
Eap CB, Vandenberghe F, Choong E, Saigi-Morgui N, Ambresin AE, von Gunten A, Conus P. Clinical and pharmacogenetic study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. Poster presented at the 2012 World Congress of the International College of Neuropsychopharmacology; June 2012. Stockholm, Sweden. [abstract] Int J Neuropsychopharmacol. 2012 Jun 1; 15(Suppl 1):101. doi: 10.1017/S1461145712000508
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Williams VS, Feltner D, Hill C, Morlock R. Evaluation of a global anxiety – Visual analog scale (ga-vas) in a clinical trial comparing lorazepam and paroxetine in patients with gad. Poster presented at the CINP 25th Biennial Congress; July 2006. [abstract] Int J Neuropsychopharmacol. 2006 Jul; 9(Suppl 1):S118.
Longo C, Raskin J, Gilsenan AW, Corey-Lisle P, Hopkins JS, Sherrill BH. Prevalence of treatment-resistant depression in Saskatchewan - limitations of a claims-based analysis. Int J Neuropsychopharmacol. 2002 Jun 1;5(Suppl 1):S141. doi: 10.1017/S1461145702003176